Product Information

Registration Status: Active

HUMIRA SOLUTION FOR INJECTION 80MG/0.8ML (PREFILLED SYRINGE) is approved to be sold in Singapore with effective from 2020-03-19. It is marketed by ABBVIE PTE LTD, with the registration number of SIN15915P.

This product contains Adalimumab 80mg/0.8mL in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.

This product is manufactured by Vetter Pharma-Fertigung GmbH & Co. KG (Schützenstrasse) in GERMANY, andAbbVie Biotechnology Ltd (ABL) in UNITED STATES.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons [L1306].


For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.

Mechanism of Action

Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.


* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]

Active Ingredient/Synonyms

Adalimumab (genetical recombination) | adalimumab-adbm | adalimumab-atto | Adalimumab |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank